AR054046A1 - Formulaciones que contienen losartan y/o sus sales - Google Patents

Formulaciones que contienen losartan y/o sus sales

Info

Publication number
AR054046A1
AR054046A1 ARP060102023A ARP060102023A AR054046A1 AR 054046 A1 AR054046 A1 AR 054046A1 AR P060102023 A ARP060102023 A AR P060102023A AR P060102023 A ARP060102023 A AR P060102023A AR 054046 A1 AR054046 A1 AR 054046A1
Authority
AR
Argentina
Prior art keywords
salts
granulate
tablets
losartan
magnesium stearate
Prior art date
Application number
ARP060102023A
Other languages
English (en)
Inventor
Perez Sergio Llorente
Original Assignee
Combino Pharm Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Combino Pharm Sl filed Critical Combino Pharm Sl
Publication of AR054046A1 publication Critical patent/AR054046A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente se relaciona en general, con nuevas formulaciones y unidades de dosificacion que contienen losartán y/o sus sales (por ejemplo losartán potásico) que son utiles para el tratamiento terapéutico (que incluye tratamiento profiláctico) de mamíferos, incluyendo a humanos, y con un proceso para hacer eso mismo. El proceso generalmente incluye (i) combinar y mezclar losartán potásico y una primera porcion de al menos uno de entre almidon pre-gelatinizado, celulosa microcristalina y estearato de magnesio con la combinacion del paso (i); (ii) compactar la mezcla que se obtuvo en el aso (i) para formar un aglomerado; (iii) desunir el aglomerado con el objetivo de obtener un granulado; (iv) agregar, al granulado, monohidrato de lactosa y una segunda porcion de al menos uno de entre almidon pre-gelatinizado, celulosa microcristalina y estearato de magnesio y mezclar; y (v) moldear la combinacion granulada en tabletas. El proceso puede incluir, además, recubrir las tabletas que se prepararon con un material de recubrimiento apropiado.
ARP060102023A 2005-05-18 2006-05-18 Formulaciones que contienen losartan y/o sus sales AR054046A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US68196105P 2005-05-18 2005-05-18

Publications (1)

Publication Number Publication Date
AR054046A1 true AR054046A1 (es) 2007-05-30

Family

ID=37809252

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060102023A AR054046A1 (es) 2005-05-18 2006-05-18 Formulaciones que contienen losartan y/o sus sales

Country Status (5)

Country Link
US (1) US20090215756A1 (es)
EP (1) EP1906936A2 (es)
AR (1) AR054046A1 (es)
CA (1) CA2609026A1 (es)
WO (1) WO2007026261A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200836774A (en) * 2007-02-01 2008-09-16 Takeda Pharmaceutical Solid preparation
TR200703568A1 (tr) * 2007-05-24 2008-07-21 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Valsartan formülasyonları
EP2405899A2 (en) * 2009-03-11 2012-01-18 Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi Valsartan formulations
EP2409683A1 (en) 2010-07-06 2012-01-25 KRKA, D.D., Novo Mesto Stable aqueous formulations comprising poorly water soluble active ingredients
CN105395509A (zh) * 2015-12-16 2016-03-16 宁波美诺华天康药业有限公司 一种氯沙坦钾片的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0511767A1 (en) * 1991-04-29 1992-11-04 Merck & Co. Inc. Tablets containing compound DUP753
EP0910375B1 (en) * 1996-06-24 2002-05-02 Merck & Co., Inc. A composition of enalapril and losartan
AU2003256419A1 (en) * 2002-08-21 2004-03-11 Merck & Co., Inc. Combination therapy using a dual ppar alpha/gamma agonist and an angiotensin ii type i receptor antagonist
WO2004066997A2 (en) * 2003-01-30 2004-08-12 Lek Pharmaceuticals D.D. Preparation of new pharmaceutically suitable salt of losartan and forms thereof with new purification and isolation methods

Also Published As

Publication number Publication date
EP1906936A2 (en) 2008-04-09
CA2609026A1 (en) 2007-03-08
WO2007026261A2 (en) 2007-03-08
WO2007026261A3 (en) 2008-01-03
US20090215756A1 (en) 2009-08-27

Similar Documents

Publication Publication Date Title
AR054046A1 (es) Formulaciones que contienen losartan y/o sus sales
Joseph et al. IP 3 receptors in cell survival and apoptosis: Ca 2+ release and beyond
AR055561A1 (es) Comprimidos con dispersion mejorada de la sustancia farmacologica
TNSN07415A1 (en) Extrusion process for making compositions with poorly compressible therapeutic compounds
PE20050686A1 (es) Formulacion para compresion directa y proceso
MX2008012731A (es) Tabletas de paracetamol de liberacion rapida.
SG160364A1 (en) Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
ECSP099529A (es) Inhibidores de cinasa mapk/erk
AR063429A1 (es) Anticuerpos anti- htnfalfa cristalinos
CR9949A (es) Inhibidores de proteina activadora de la 5-lipoxigenasa (flap)
AR057099A1 (es) Una forma cristalina, un proceso de preparacion y composicion farmaceutica
MX2007006284A (es) Acidos biariloximetilarenocarboxilicos.
BRPI0513702A (pt) comprimidos revestidos gelatinosos que se desintegram rapidamente
UA88943C2 (ru) Быстрый способ влажного гранулирования для получения композиций, которые содержат кальций
AR083328A1 (es) Particula de suministro
WO2022013610A3 (en) Radiopharmaceutical and methods
CL2012000374A1 (es) Metodo para la preparacion de una composicion saborizante activa que comprende una primera reaccion entre un compuesto amino y un carbonilo, resultando una primera mezcla de intermediarios, una segunda reaccion con un segundo compuesto amino solo o en combinacion con un compuesto carbinilo, resultando una segunda mezcla de intermediarios, reacciones serparadas adicionales con compuestos de otras clases quimicas, ultima reaccion que comprende una mezcla de todas las mezclas de intermediarios anteriores.
BR112014015060A2 (pt) método para produzir masterbatches
NI200700139A (es) Formulaciones de benzoxazoles sustituidos
CO6190600A2 (es) Metodo para formar una tableta que comprende el premezclado de ibuprofeno y silice
PL1842900T3 (pl) Tabletka środka piorącego i/lub czyszczącego
SE0200154D0 (sv) New process
AR066000A1 (es) Procedimiento para preparar comprimidos de dihidrocloruro de pramipexol
AR065853A1 (es) Composicion farmaceutica formada por granulos de sal de azidocitidina. proceso.
DE60220551D1 (de) Tabletten mit verzögerter wirkstofffreisetzung enthaltend indapamid

Legal Events

Date Code Title Description
FB Suspension of granting procedure